Delamanid is one of only two new drugs against tuberculosis, which appeared in the last half century. It is effective against the most dangerous forms of tuberculosis that are resistant to many other drugs.
That treatment-resistant tuberculosis (DR-TB) effective delamanid must be taken with several other drugs. You alone (without delamanidu) stands between one thousand to 4.5 thousand US dollars per course of treatment, so if we are talking about the lowest prices destined for developing countries. And these sums are, however, for local governments too high. To be able to significantly expand the treatment of drug-resistant TB, the cost should be around $ 500 per course of treatment, warn MSF.
States that are eligible for grants from the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), will be able to buy delamanid as $ 1,700 per course of treatment. Drug must be registered in, or he should be granted an exemption for import.
To this date, the company Otsuka registered delamanid only four countries (Germany, Japan, South Korea and the UK), but none of them belong to countries heavily burdened resistant tuberculosis. The pharmaceutical company should therefore register delamanid in countries that are burdened resistant tuberculosis, and in countries where clinical trials have been performed for this drug. The agreement between the Global Drug Facility (GDF, the mechanism of the World Health Organization to mediate anti-TB drugs) and Otsuka remember to countries that do not qualify for grants from the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM). That, however, include countries heavily burdened by tuberculosis, such as the Russian Federation or the Philippines.
"Countries should start expanding treatment for people with drug-resistant TB using the most effective available léků.Delamanid but today in most states is neither affordable nor in them is not available," said the doctor Grania Brigden, campaign advisor for MSF called Access. " price per delamanid must fall on the available úroveň.Otsuka should also promptly register delamanid in all countries where this drug has been clinically tested, and not least in countries heavily burdened by tuberculosis. If people do not have access to delamanidu, this new drug virtually worthless, "she added.
It is estimated that up to two-thirds of the nearly half a million people each year become ill resistant tuberculosis could benefit delamanid. However, the drug approval are for two years and it got only 180 people. "For Otsuka should be a priority in order to cure more people have access, which can save lives. It should be made every effort to make this promising new drug benefit to the greatest number of people. Today, unfortunately, not seeing anything like this, "said Grania Brigden.
MSF is dedicated to treat tuberculosis (TB) thirty years and treat MDR-TB since 1999. They are one of the largest non-governmental organization that provides tuberculosis treatment. In 2014 they treated more than 23,000 tuberculosis patients, including 1,800 patients with resistant form. In their programs they would like to increase the use of the drug delamanid. In December last year, received as a gift a certain amount delamanidu for their projects and associations Stop TB Parnership.
Source: tz LBH
